Ophthalmology

This approval was granted to generic pharmaceutical company Akorn Operating Company, LLC.

Hydroxyurea therapy was associated with decreased rates of retinal thinning and could be a protective factor.

Eysuvis 0.25% is the first and only approved prescription therapy for short-term treatment of signs and symptoms related to dry eye disease.

Low and moderate dosing shows the most potential in preventing AMD for patients with diabetes.

Patients treated with the bispecific antibody at fixed intervals of 16 weeks achieved visual acuity outcomes comparable to 8-week interval treatment of aflibercept.

The researchers unexpectedly found sustained visual improvement in both eyes, despite only 1 eye being treated with AAV.

Primate model studies show the procedure can be done safely and without losing eye function. Which patients may benefit first?

Primary care physicians should be aware of which patients are at high risk for developing glaucoma.

Up to 83% of evaluated individuals indicated that their ocular symptoms began within two weeks of their other COVID-19 symptoms

A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.

Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.

A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.

RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

Lynn Hassman, MD, talks about a promising new technology that can optimize precision medicine in patients with uveitis.

New findings suggest the common ophthalmic disorder in premature infants could be three-fold more prevalent in multiracial infants.